StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
ADCTADC Therapeutics SA
stockpulse.co.kr
NYSE
$1.44▼ 0.35%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $183.2MShares out 1.300M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

3
  • 10.13Pre-market26.10.13 19:26
    8-KKey event#●●●#●●●#●●●

    ADC Therapeutics SABullish

    ADC Therapeutics has finalized a private placement to raise $86.6 million by issuing 12,911,347 common shares and pre-funded warrants for 48,088,653 shares. The company also amended its loan and royalty agreements, prepaying $70 million in debt to reduce the outstanding principal to $50 million and adjusting financial covenants. These transactions include significant warrant repricing and structural changes that may lead to shareholder dilution.…more

    $1.44-0.35%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 8.13Pre-market26.08.13 22:14
    8-KKey event

    ADC Therapeutics SA

    ADC Therapeutics reported $18.6 million in net product revenue for Q2 2026, while facing significant FDA concerns regarding clinical benefit and Grade 5 event imbalances in the LOTIS-5 Phase 3 trial. Consequently, the company is implementing a 17% workforce reduction to save approximately $10 million annually and is currently reassessing its regulatory strategy for ZYNLONTA.…more

    $1.44-0.35%vs prev close
    View filingShare
  • 7.27After-hours26.07.28 05:25
    SCHEDULE 13GOwnership

    ADC Therapeutics SA

    BlackRock, Inc.가 ADC Therapeutics SA의 지분 5% 이상을 보유한 대량보유자임을 공시했습니다. 이번 Schedule 13G 제출은 기관 투자자의 지분 확보 사실을 시장에 알리는 것으로, 향후 해당 기업의 지배구조 및 주가 흐름에 영향을 미칠 수 있습니다.…more

    $1.44-0.35%vs prev close
    View filingShare

2 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 10.8Pre-market26.10.08 22:07
    Bullish#●●●#●●●#●●●

    ADC Therapeutics Announces $86.6M PIPE Financing and Debt Restructuring…more

    ADC Therapeutics has secured $86.6 million through a PIPE financing deal while simultaneously amending its loan and royalty agreements. The transaction involves significant share issuance and warrant grants, leading to potential equity dilution.…more

    $1.44-0.35%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga